Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Roche company Genentech to identify and advance novel RNA-targeted small molecule therapeutics.

Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.

U.S. deaths from the coronavirus pandemic surged past 2,000 for two days in a row as the most dangerous season of the year approached, taxing an overwhelmed healthcare system with U.S. political leadership in disarray.

Arteric is a digital marketing agency that serves life science and healthcare brands throughout their life-cycle, from digital recruitment of participants for clinical trials through commercialization and healthcare delivery. According to management, 2019 and 2020 have been breakout years for the agency.

BioSpace reviews some recently published scientific studies, including researchers with the University of Colorado Anschutz Medical Campus releasing a new study calling attention to the emergence of mosquito-borne viral outbreaks in West Africa.

Two years after Boston-based HotSpot Therapeutics launched, the company secured $65 million in Series B funding to advance the development of allosteric therapies that target “regulatory hotspots” in the body into the clinic.

At an outer suburban manufacturing plant, engineer Byron Kennedy is resetting a machine to spray-print a layer of copper on to a door handle, aiming to use the metal’s antiviral properties to counter the threat of the COVID-19 pandemic.

Origin, a 3D printing specialist for medical devices, completed clinical trials and validation of the company’s 3D-printed nasopharyngeal swabs for use in COVID-19 test kits.

Researchers with Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, were able to grow natural-looking hair that grows through the skin using human induced pluripotent stem cells (iPSCs).

Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.